ERBB2 and breast carcinoma: In concordance with that finding, the group of M.J. Bissell could clearly demonstrate that the response of ErbB2 overexpressing breast cancer cell lines to trastuzumab, pertuzumab and lapatinib was significantly different in 2D and 3D cultures [154].